Cognition Therapeutics, Inc. announced that a manuscript entitled, “A Phase 1b Randomized Clinical Trial of CT1812 to Measure Aß Oligomer Displacement in Alzheimer's Disease Using an Indwelling CSF Catheter” (doi: 10.1186/s40035-023-00358-w) has been published in the journal, Translational Neurodegeneration. Findings from the SNAP study demonstrate that a single oral dose of CT1812 rapidly displaces Aß oligomers from synapses. This was shown by a marked temporal increase in CSF Aß oligomer levels after a single dose of CT1812.

In comparison, no change was observed in Aß oligomers levels following administration of placebo. In this study of three individuals with Alzheimer's disease, CT1812 was well-tolerated, and no serious adverse events were related to study medication, but instead were due to the lumbar puncture procedure for the indwelling catheter used for CSF sampling. Clinical results from the SNAP study mirror preclinical findings that showed that Aß oligomer levels in the CSF of transgenic mice could be increased after a single dose of CT1812 (Izzo et al., Alzheimer's Dement, 2021).

in vitro studies, the displacement of oligomers by CT1812 resulted in the restoration of synapses, which in a preclinical Alzheimer's model was associated with an improvement in cognitive function. The SNAP study was a randomized, double-blind, placebo-controlled trial of CT1812 in three adults with mild-to-moderate Alzheimer's disease. Enrolled patients had an indwelling catheter placed in the lumbar CSF space, from which CSF samples were collected hourly for 28 hours.

Five samples were collected prior to administration of a single 560 mg oral dose of CT1812, or placebo and 24 samples were collected following administration. Aß oligomer levels were measured via microimmunoelectrode and native Western Blots assays.